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SEVERAL natural  components  abundant  in  the  fluid
phase of human breast-milk have been shown to be
inhibitors of complement activation in vitro, partic-
ularly the classical pathway. These include lysozyme,
lactoferrin, lactalbumin alpha and other ligand chela-
tors, complement regulator proteins and other spe-
cific  soluble  inhibitors  of  complement  activation.
Their physiological significance probably resides in
their ability to restrict in vivo complement activation
to specialized (compartmentalized) sites on the cel-
lular  membrane  structures  in  human  milk,  repre-
sented by the abundant surface area of the milk fat
globule  membranes.  This  would  serve  to  prevent
inflammatory-induced tissue damage of the delicate
immature  gastrointestinal  tract  of  the  newborn as
well  as  the  mammary  gland  itself.  A  number  of
recognized and potential inhibitors of complement
activity in human milk and other biological fluids are
hereby  reviewed,  with  a  proposal  of  their  physio-
logical significance.
Abbreviations: HBM, human breast-milk; APC, alternative
complement activation  pathway;  MAC,  membrane  attack
complex (C5b-9); MFGM, milk fat globule membrane
Key  words:  Human  breast-milk,  complement  system,
inhibitors, milk fat globule membrane
Introduction
The serum complement (C) system consist of at least
19 proteins, mostly in pre-activated enzymatic forms,
activated in a multi-step cascade reaction via either
the classical or alternative pathways (Figure 1). The
classical  pathway  is  activated  mainly  by  antigen–
antibody complexes (IgG or IgM mostly) starting with
C1q.1 The alternative pathway  (APC)  utilizes  active
sites (such as are present on zymosan, yeast, cobra
venom,  Gram-negative  bacteria, sheep  erythrocytes
and  human  cells  deficient  in  the  expression  of
regulatory molecules) in the presence of properdin,
serum  factors  B  and  D,  to  activate  C3.  The  two
pathways proceed uniformly after C3 activation to the
formation  of  (C5b-9)  membrane  attack  complexes
(MAC),  capable  of  inserting  into  biological  mem-
branes and producing cell lysis and death.2
The immunochemical levels of certain complement
components in the human colostrum (C3, C4) have
been  found  to  approach  that  of  normal  serum
levels.3–5 However, only a small fraction of the serum
complement  activity  is  measurable  using  in  vitro
assays. A number of factors might be accountable for
this  effect.  Firstly,  there  is  apparently  a  relative
deficiency of some of the essential components of the
complement  cascade system.  For  example,  proper-
din,  a  stabilizer  of  fluid-phase  alternative  pathway
convertases, has been reported to be either absent in
human breast-milk (HBM), or only present in minute
quantities less than 1m g/ml.6 It is also possible that
some  of  the  identifiable  complement  components,
though native, might  be  haemolytically  and physio-
logically  inactive.7 Thirdly,  there  is a  wide  array  of
natural human  breast-milk components which have
been shown to inhibit complement activity in vitro.
It has been observed that cow’s milk contains some
inhibitory  effect  on  the  activity  of  serum  comple-
ment. This inhibitory effect in bovine milk has been
partly ascribed to a prozone phenomenon of exces-
sive  antibodies  in  undiluted  milk,  and  other  unex-
plained factors in heated milk, particularly in casein
micelles.8,9 A similar inhibitory effect of breast-milk
on  the  serum  complement  activity  has  also  been
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effect appears to reside mainly in its fat component.10
This  inhibitory  activity  presents  unequivocal  evi-
dence for the presence of anti-complement factors in
human milk (Table 1).
Soluble Inhibitors of Complement
Activation in Human Breast-Milk
a -Lactalbumin and ligand ion chelators
Some milk proteins, such as a -lactalbumin, and low-
molecular weight ligands, such as citrates and phos-
phates, are known to have high affinity binding sites
for calcium.11 They may therefore act as inhibitors of
complement indirectly by chelating the divalent ions
required for complement activation.12
Lactoferrin
Lactoferrin  is  a  glycoprotein  with  an  approximate
MW  of  80kDa.  It  is  produced  by  epithelial  cells,
neutrophils and monocyte macrophages. It is present
as a major antimicrobial  component of many  body
fluids,  including  tears,  saliva,  seminal  fluid  and
pancreatic secretions. The  highest  concentration of
lactoferrin (up to 6mg/ml) is found in the colostrum
and  this  gradually  falls,  as  lactation  proceeds,  to  a
constant value in mature milk (approx. 1mg/ml) after
about  4  months  of  lactation. It  is  resistant to  acid
denaturation during its passage through the intestinal
tract.3,4
Lactoferrin  in  tears  from  humans  and  several
animals  has  been  shown  to  inhibit  the  classical
pathway of complement activation, by preventing the
formation  of  C3/C5  convertase.  It  competitively
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FIG. 1. Diagrammatic representation of the classical and alternative pathways of complement activation.inhibits  the  binding  of  C2  to  EA14  cells.  This
inhibitory effect is dose-dependently reversed by the
addition of Fe3+ ions.13,14
Lysozyme
Lysozyme is an acid- and heat-stable enzyme that is
abundant  in  the  breast-milk  and  in  most  other
mucosal body fluids. The concentration of lysozyme
in the colostrum is approximately 40–100m g/ml and
gradually increases as the lactation progresses.3,4
Lysozyme  catalyzes  the  hydrolysis  of  the  b (-1,4-)
linkage  between  N-acetylglucosamine  and  N-acetyl-
muramic acid in the bacterial cell wall. The enzyme
lyses mostly Gram-positive and a few Gram-negative
bacteria,  or  induces  their  aggregation.  Lysozyme
interacts with other immunoprotective components
of human milk in exerting its antimicrobial actions. It
is bacteriocidal for E. coli and Salmonella spp. in the
presence of sIgA and C3 complement component.
Lysozyme has been found  to inhibit  the classical
pathway  of  serum  complement  activity  in  a  dose-
dependent  fashion,  especially  within  the  range  of
pathological concentrations. The inhibitory effect of
lysozyme  seems  to be minimal  under  physiological
conditions in the absence of inflammation, since only
a minimal inhibition was produced within this physio-
logical range. The inhibitory effect of lysozyme might
be related to its ability to degrade certain glycoprotein
components of native complement factors.15
Native and aggregated immunoglobulins
IgA  is  the  most  abundant  immunoglobulin  in  the
colostrum and breast-milk, and constitutes the major
protein content in the colostrum.3,4 It has been long
argued that IgA activates neither the classical nor the
alternative complement pathway. Subsequent experi-
ments,  however,  have  shown  that  it  is  capable  of
limited  activation  of  the  complement  system.  IgA
myeloma  has  been  shown  to  activate  the  classical
pathway.16 Aggregated  IgA  and  IgA  coated  onto
plastic  (possibly  denatured), but  not  antigen-bound
IgA have also been shown to activate the alternative
pathway of complement (APC).17 Fab  fragments of
IgA  have  also  been  previously  discovered  to  be
capable of activating the APC.20
In  a  solid-phase  antigen-dependent  C3b-binding
ELISA system, IgA antibodies were unable to activate
complement by either pathway. IgA antibodies were
found to inhibit significantly the activation of comple-
ment initiated by antigen-bound polyclonal or mixed
monoclonal IgG antibodies. This inhibition was found
to be independent of the ability of the IgA antibodies
to compete against the IgG antibodies in binding to
either antigen or C1q.18,19
IgA Fab fractions have also been found to inhibit
the  activation  of  complement  system. The  invasive
pathogenicity of  certain mucosal bacteria has been
postulated to be related to their possession of IgA1
proteases, which cleave secretory IgA1 antibodies to
antigen-binding Fab-a fragments. These fragments are
not only defective in mucosal defence properties, but
also  protect  the  organisms  from  other  immune
effector  systems,  such  as  the  classical  pathway  of
complement activation.18
Soluble forms of membrane complement
regulatory proteins
Protectin  (CD59),  a  cell  surface  complement  reg-
ulatory  protein,  that  binds  and  inactivates  the
A review of inhibitors of complement activity in human breast-milk
Mediators of Inflammation · Vol 8 · 1999 71
Table 1 List of proven and possible inhibitors of complement activity in human breast-milk
Breast-milk component Effect on complement activity Ref.
Lactoferrin Inhibits the assembly of the classical C3/C5 convertase 13,14
Fat globule membrane Non-specific target surface for active C fragments 10
Free lipids in solution Chelation of calcium and magnesium, non-specific binding
of lipophilic C fragments
12,34
Soluble protectin (CD59) Inhibits MAC formation 21,22
Poly IgA and antigen-bound IgA Inhibits IgG-mediated complement activation 18,19
Proteases Non-immune complement consumption 18,27,28
Bacteria and other pathogenic contaminants Consumption of classical or alternative path C components 30,31
Citrates, phosphates and proteins Binding of ionic calcium required for optimal C activity 11,12
Lysozyme Binding of ionic calcium required for optimal C activity,
Hydrolysis of native C components
11,12,15
a -Lactalbumin Binding of ionic calcium required for optimal C activity 11,12
Soluble IgG-, IgM-antigen complexes Fluid-phase complement consumption
Other unidentified factors Non-specific C consumptionmembrane attack complex (MAC), has recently been
discovered to be secreted and embedded in milk fat
globules.21 It  is  also  present  in  soluble  forms  in
human  milk.22 The  soluble  forms  could  have been
shed from the milk fat membrane, and possibly could
also  partly  arise  from  aging  neutrophils  in  breast-
milk.23 The  extent  of  the  inhibitory  effect  of  this
protein  under  physiological  conditions,  however,
remains  unknown.  Decay-accelerating  factor  (DAF)
has been detected on most epithelial cells at sites of
mucosal  immunity,  and  its  soluble  form  has  been
found  in  various  body  fluids.24 This  complement
regulatory  molecule  has,  however,  not  yet  been
specifically  reported in breast-milk or on mammary
gland epithelial cells. Vitronectin, which has also been
detected in  human  tears, is yet to be described in
human breast-milk.25
Other specific complement cascade inhibitors
Factor  H  has  been  measured  immunochemically  in
the  human  milk,26 its  serum  level  being  approx-
imately 0.233m g/ml (0.12%). It is a specific inhibitor
of the APC, and its relatively low level in human milk
might raise doubts as to its physiological significance
on mucosal complement activity. In our laboratory,
C1-INH could not be detected in human milk, using a
single radial immunodiffusion method with a detec-
tion limiting value of 0.048g/l. Factor I (C3 inactiva-
tor) has also not been reported previously in human
breast-milk.
Milk proteases as possible inhibitors of
complement activation
Heat-stable  milk  proteases,  including  plasmin,  are
present in breast-milk. They have been shown to be
capable of splitting b -casein in milk,27,28 and could
contribute to the complement-inhibitory activity of
human milk by non-immune splitting of native com-
plement components.
Other potential inhibitors
There is no conclusive evidence to suggest that all the
possible  inhibitors  of  complement  system  in  milk
have  been  identified.  Further  research  might  yet
discover many other unidentified natural components
or contaminants, which directly or indirectly contrib-
ute  to  the  observed  diminution  of  inflammatory
reactions on the mucosal surfaces, in the presence of
active  potentially  inflammatory  protective  mecha-
nisms. This would be in line with the mucosal anti-
inflammatory hypothesis proposed by Goldman and
co-workers.29 However,  their suggestion  of  insignif-
icant  functionality  of  complement,  based  on  the
assumption of minimal levels in human milk, would
not be supported by the discovery of levels of certain
complement  components  approaching  those  avail-
able in serum. The presence of such a wide array of
inhibitors, apparently serve teleologically to minimize
the undesirable inflammatory processes, while  per-
mitting  the  infant  to  benefit  from  the  other  non-
inflammatory activities of the complement.
Bacterial  and  other  pathogenic  contaminants  of
human milk might indirectly constitute a source of
complement  depletion,  by  wasting  the  potentially
useful native components, and diminishing the levels
effectively  delivered  to  the  nursing  infant.  This  is
particularly so, based on the observation that human
milk is rarely sterile, often moderately contaminated
with  non-pathogenic  normal  skin  flora.30 It  also
sometimes contains potential pathogens, which how-
ever seem to produce no ill effects on the suckling
infant.31
Similarly,  soluble  IgG  or IgM  complexes, with or
without  antigens,  secreted  into  the  milk  from  the
mother’s blood circulation, could potentially activate
and deplete the mucosal complement.
Milk Fat Globule Membrane as an Inhibitor
of Breast-Milk Complement
Human milk consists mainly of a protein, sugar and
cellular  suspension  in  95%  water  and  2–5%  lipid
fraction.  The  cellular  elements  consist  of  macro-
phages,  neutrophils,  lymphocytes  and  mammary
gland  epithelial  cells.  The  lipid  fraction  consists
mainly of triglycerides enveloped in a complete tri-
laminar unit of biological cell membranes, the milk fat
globule  membrane  (MFGM).  This  membrane  is
derived from the apical region of the mammary gland
epithelial cells,  and  is  budded  off  around  the  milk
lipids as they are being secreted by the cells.32 The
MFGM  is  similar  to  any  other  cell  membrane  of
eukaryotic cells33
The inhibitory effect of human milk has been found
to be progressively diminished with increasing speed
of  centrifugation  and  the  degree  of  de-fattening.10
Two possible explanations have been proposed for
these  observations.  The  MFGM  might  be  either
activating  the  complement  reaction  cascade,  and
thereby depleting  serum  complement  components,
or acting as an alternative reaction site, preventing the
assembly of the active complement components on
the target sheep red blood cells (SRBC).
Free fatty acids (FFA)  in milk are also capable of
forming  soaps  with  calcium  and  magnesium  ions,
thereby preventing optimal activation of the comple-
ment system reaction cascade.12,34 They could also
bind  to  the  more  lipophilic  components  of  the
complement  system,  preventing  them  from  partici-
pating in activation reactions by making them chem-
ically inactive.
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Human Breast-Milk
Despite the levels of some components comparable
to those in serum, activation of human milk comple-
ment in the fluid phase has been found to be less than
optimal  under  physiological  conditions,  requiring
additional divalent cations. However, in vitro activ-
ities of human milk complement have recently been
demonstrated,  including  haemolysis  of  sensitized
SRBC and bacteriolysis of a serum-sensitive E. coli, S.
aureus and  S.  epidermidis.  Furthermore,  non-
immune mechanisms of complement activation have
been demonstrated in the mucosal secretions of the
lachrymal gland,35 suggesting  that the inhibition  of
classical pathways of complement activation at these
mucosal sites could still be circumvented, to enable
some of the physiological roles of the complement to
be realized.
Apart  from  the  complement  and  free  fatty  acids
(FFA),  most of the available antimicrobial agents in
human milk are bacteriostatic. Since bactericidal FFA
are also present in  the artificial  formula  feeds, and
they do not seem to contribute to the protection of
formula-fed infants,36 the complement system should
be regarded as potentially the source of a significant
contribution to the increased resistance of breast-fed
infants against infection;37 Furthermore, clinical stud-
ies have shown that a deficient secretion of comple-
ment components in human milk constitutes a higher
risk  factor  for  the  development  of  mastitis  in  the
lactating mother.38 Breast-fed infants are also known
to possess higher levels of complement components
and activities compared to their formula-fed counter-
parts.44 Human milk, therefore, constitutes an impor-
tant  source  of  either  native  components, absorbed
from the infantile intestines, or some other humoral
factors  capable  of  enhancing  the  synthesis  and
activities of the complement system in vivo.
The  levels  of  both  mucosal  lysozyme  and  most
other  soluble  inhibitors  tend  to  increase  during
periods of infection in parallel with the complement
components.38 Their inhibitory effects under physio-
logical conditions might, therefore, be expected to be
minimal, and sharply increase with the onset of full-
blown  infections.  The  protective  functions  of  the
various body defence factors at the mucosal surfaces,
including  those  in  the  human  milk,  have  been
proposed to be carried out mainly with the exclusion
of inflammatory processes.29 Increased overall phys-
iological activities of these mucosal factors would be
an indication for a greater need for the suppression of
inflammatory components of  their activities, hence
the need for increased inhibitory activities.
The observation of specific physiological functions
attributable  to  the  complement  system,  as  listed
above, in the presence of soluble inhibitors, would
suggest  that  the  mucosal  complement  might  be
actively  involved  in  such  activities  as  bacteriolysis,
opsonization and  immuno-adherence,  neutralization
of certain viruses, as well as modulation of immune
responses at mucosal surfaces (see Figure 1), in the
absence of, or with the suppression of inflammatory
processes.39 This  would  serve to  protect  the  body
against the constant threat of  foreign  invaders. The
presence  of  secretory  anti-complementary  compo-
nents would then serve to protect the tissues against
secondary damage during acute overwhelming infec-
tions, where excessive inflammatory reactions of the
complement might be undesirable.
An Hypothetical Viewpoint of the
Physiological Mechanisms of Human
Breast-Milk Complement Activation and
the Role of Milk Fat Globule Membrane
The presence of such a wide variety of potent soluble
inhibitors of  complement  activity  in  human  breast-
milk,  particularly  those  of  the  classical  pathway,
would prevent their optimal physiological activities in
the fluid phase. However, clinical and experimental
evidence  suggest  that  the  complement  system  is
physiologically active in vivo.38,44 The activation of
the complement might, therefore, be expected prefer-
entially to take place outside the fluid phase, on the
surface of any widely available solid phase, such as
milk  fat  globule  membranes,  with  the  alternative
pathway being favoured over the classical pathway.
In  vivo,  MFGM  appears  to  be  the  most  suitable
template  for  complement  activation,  where  all  the
products of  complement activation could be  segre-
gated  together  to  obtain  a  relatively  high  local
concentration and maximal effect on the membrane-
bound  antigens.  A  number  of  observations  and
assumptions point to the possible role of the MFGM
as the major site of complement activation in vivo.
Firstly,  the MFGM  possesses independent mecha-
nisms for the sequestration and trapping  of  certain
pathogenic  bacterial  antigens  by  attachment  to  its
surface glycoproteins.40 Secondly, our recent studies
have provided evidence that many  native  and  acti-
vated products of complement are closely bound to
the MFGM. For example, in a modified CH50 assay,
where  non-specific  haemolytic  effects  of  FFA  have
been inhibited, up to 50% of complement activity is
lost by de-fattening of whole-milk through centrifuga-
tion.  The  unidentified  components  of  cow’s  milk
capable  of  preferentially  binding  to  C1q  might  be
represented in human milk by the MFGM.41 Thirdly,
protectin (CD59), a membrane surface complement
regulatory molecule, has been found to be expressed
on the MFGM.21 Homologous cells are protected from
the lytic effect of complement through the expression
of surface membrane regulatory molecules, such as
decay-accelerating factors (DAF,  CD 55),  membrane
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reactive lysis  (protectin, CD 59), C3 receptors 1, 3
and  4  (CD35,  CD11b,  c/18). This  would  suggest  a
physiological  mechanism  by  which  the  MFGM  is
protected  in  vivo,  at  least  by  protectin,  in  the
presence  of  ongoing  antigen-induced  complement
activation, without leading to a secondary damage of
the MFGM. Lastly, most milk-borne macrophages are
found to be laden with fat vacuoles which they have
ingested in vivo.42,43The explanation for this observa-
tion would seem to be based on the deposition of C3
fragments  or  IgG  on  the  MFGM,  which  opsonizes
them for phagocytosis by macrophages.
The abundant supply of MFGM in human milk and
its  ability  to  bind  to  both  native  and  activated
complement  components,  as  well  as  particulate
antigens,  which  are  also  able  to  independently
activate the alternative pathway, even in the absence
of specific antibodies, makes MFGM the most likely
site for physiological activation of human milk com-
plement. While  pathogens  to  which  the  mother  is
already sensitized might be disposed of by the large
amounts of secretory IgA (sIgA) in breast-milk, newly
acquired  antigens  from  the  environment,  which
might  not  be  able  to  immediately  stimulate  the
production of specific antibodies at the mucosal site,
could  be  attacked  by  the  breast-milk  complement
through  the  aid  of  the  MFGM,  thereby  protecting
both  the  mammary  gland  and  the  suckling  infant
against infection.
The  MFGM  might  assume  particular  significance
when  the  level  of  particulate  antigens,  such  as
bacteria, overwhelm the inhibitory ability of the sIgA
and the other bacteriostatic components of  human
milk fluid-phase. They are then available to be bound
on  the  surface  of  the  MFGM  where  they  could
activate the complement system and subsequently be
killed by lysis, without significant interference of the
wide variety of inhibitors present in the fluid phase.
The  ability  of  the  MFGM  to  bind  C3  opsonin
fragments,  thereby  enhancing  its  phagocytosis  and
ultimate degradation by macrophages, might account
for  at  least  one  of  the  mechanisms  by  which  it  is
ultimately destroyed along the intestinal tract of the
suckling infant.
Conclusion
Research in the field of complement system reactivity
in  human  breast-milk  is  at  a  relatively  early  stage.
Further efforts are likely to lead to the discovery of
many  interesting  interactions between  complement
components and other natural components of human
milk. The physiological  significance  of  the  comple-
ment  in  protecting  the  mammary  gland  and  the
nursing infant can no longer be denied. The presence
of a wide range of inhibitors of complement probably
serve  to  limit  the  activation  of  the  complement
system  in  the fluid-phase, avoiding the  consequent
risk  of  widespread damage to  soft  tissues  by  asso-
ciated inflammatory processes, while promoting the
solid-phase  activation  of  the  reaction  cascade. The
milk  fat  globule  membrane  thereby  acts as  a  most
suitable  template  to  support  the  solid-phase
reactivities.
Understanding the actual mechanisms of the com-
plement reaction cascade and interaction with such a
wide  variety  of  inhibitors  present  in  the  aqueous
phase  of  human  milk,  is  the  real  challenge  for
investigators in the coming decades.
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